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1 ZUSAMMENFASSUNG 
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1 ZUSAMMENFASSUNG 
Diphenyl-2-pyrrolidinemethanol (D2PM), ein sogenanntes ‘legal high’, wurde zum ersten 
Mal 2007 in Großbritannien identifiziert. D2PM wird vor allem über Online-Shops vertrieben 
und als Stimulans missbraucht. Das Ziel der vorliegenden Arbeit war es, die Metaboliten des 
D2PM in Rattenurin mittels Gaschromatographie-Massenspektrometrie (GC-MS) oder 
Flüssigchromatographie-Hochauflösender-Tandem-Massenspektrometrie (LC-HR-MS/MS)-
Techniken zu identifizieren. Nach entsprechender Probenvorbereitung konnten mittels GC-
MS insgesamt fünf Phase-I-Metabolit identifiziert werden. Daraus konnten folgende Schritte 
im Abbau des D2PM postuliert werden: Hydroxylierung am Pyrrolidinring und Oxidation 
zum Keton, Einführung einer phenolischen Hydroxygruppe - auch in Kombination mit der 
Hydroxylierung am Pyrrolidinring. Neben den genannten Metaboliten konnte auch die 
unveränderte Muttersubstanz im Urin nachgewiesen werden. Alle postulierten Phase-I-
Schritte konnten unter Verwendung von LC- HR-MS/MS bestätigt werden. Des Weiteren 
konnten mittels LC-HR-MS/MS zwei konjugierte Phase-II-Metabolite, Phenylhydroxy-oxo 
D2PM Glucuronid und Phenylhydroxy D2PM Glucuronid, detektiert werden. Der Nachweis 
eines missbräuchlichen Konsums sollte mittels GC-MS und LC-MS
n 
möglich sein. 
 
2 SUMMARY 
Diphenyl-2-pyrrolidinemethanol (D2PM) is a so-called ‘legal high’ and appeared for the first 
time in the United Kingdom in 2007. It can be ordered from online shops and is used as a 
recreational drug. The aim of this work was to identify its metabolites in rat urine using GC-
MS and LC-high resolution-MS/MS (LC-HR-MS/MS).
 
After analysis of the urine samples, five phase I metabolites could be identified by GC-MS. 
The following metabolic steps could be postulated: hydroxylation at the pyrrolidine ring 
followed by oxidation to the ketone, introduction of a phenolic hydroxy group also in 
combination with hydroxylation at the pyrrolidine ring, and finally combination of 
hydroxylation at the phenyl ring and oxidation of the pyrrolidine ring. Besides these 
metabolites, the unchanged parent compound could be detected. 
All postulated phase I metabolites could be confirmed using LC- HR-MS/MS. Additionally, 
the formation of two phase II metabolites, phenylhydroxy-oxo D2PM glucuronide and 
phenylhydroxy D2PM glucuronide, could be shown.  
3 INTRODUCTION 
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3 INTRODUCTION  
More and more new psychoactive substances are sold via the internet as so-called “legal 
highs”.[1,2] They are widely consumed although the content of the preparations is often 
unknown or not correctly declared making the health risks assessment difficult. Such drugs 
are detected frequently in clinical and forensic samples. Diphenyl-2-pyrrolidinemethanol 
(D2PM) is one of these substances that appeared for the first time in the United Kingdom in 
2007.[
3
]
  
D2PM is a chiral structure analogue of phenethylamine (Fig. 1), a biogenic amine which can 
naturally be found in cocoa and bitter almond oil. Enantioseperation of (R-) and (S-)-D2PM 
has been described.[
4
] The desoxygenated form of D2PM, 2-(diphenylmethyl)pyrrolidine 
(DPMP, desoxypipradol) has also been found to be sold as drug of abuse.
 [5,6]
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3.1 Pharmacology and Toxicology of D2PM 
The symptoms after ingestion of D2PM were of neuropsychiatric character and resulted in 
anxiety, paranoia, and prolonged insomnia. Furthermore, sympathomimetic effects could be 
observed, such as pupil dilation, tachycardia and hypertension.[
7-9
]  
Ischemic-sounding chest pain as a consequence of ingestion of ‘Head Candy’, a D2PM 
containing preparation, has also been reported. Besides D2PM, Glaucine was detected in this 
preparation but was not held responsible for the cardiac symptoms.[
7
] According to other case 
reports, D2PM was detected in urine after consumption of diverse drugs without the 
awareness of its contents, namely ‘Benzofury’, ‘NRG-3’ (in combination with MDMA), 
‘Nytol’, and further unknown substances.[8]  
Figure 1 .  Chemical structure of D2PM and phenethylamine. 
 
  3 
After ingestion of DPMP, consumers were reported to have shown symptoms such as 
tachycardia, tachypnea, elevated creatinine kinase (CK) concentration, leukocytosis and acute 
dystonia.[
5,6
] 
The pharmacological properties of D2PM were recently reviewed by Wood and Dargan.[
9
] It 
was described to bind at the cocaine binding site of the dopamine transporter. The group of 
Wood also published case series, showing the neuropsychiatric effects after recreational use 
of D2PM. Lidder suggested cardiovascular toxicity in association with the intake of 
D2PM.[
10
] 
 
3.2 Aim of the present work 
The aim of this work was the elucidation of the biotransformation of D2PM in the rat using 
GC-MS and LC-high resolution-MS/MS (LC-HR-MS/MS) as basis for thorough screening 
procedures feasible in clinical and forensic toxicology.  
 
3 INTRODUCTION 
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4 EXPERIMENTAL PROCEDURES / MATERIAL AND METHODS 
4.1 Chemicals and reagents 
D2PM was obtained from Sigma-Aldrich (Steinheim, Germany), Isolute HCX cartridges 
(130 mg, 3 ml) from Biotage (Uppsala, Sweden), and all other chemicals and reagents from E. 
Merck, Darmstadt (Germany) and they were of analytical grade. 
 
4.2 Urine samples 
The investigations were performed using urine of male Wistar rats (Charles River, Sulzfleck, 
Germany) for toxicological diagnostic reasons according to the corresponding German law. 
They were administered a single 20 mg/kg body mass dose of D2PM for identification of the 
metabolites. Urine was collected separately from the feces over a 24 h period. All samples 
were directly analyzed and then stored at -20°C. Blank urine samples were collected before 
drug administration to check whether the samples were free of interfering compounds. 
 
4.3 Sample preparation 
4.3.1 Sample preparation for phase I metabolism studies 
A 2.0 ml portion of urine was adjusted to pH 5.2 with acetic acid (1 M) and incubated at 56°C 
for 1.5 h with 50 µl of a mixture (100 000 Fishman units/ml) of glucuronidase (EC No. 
3.2.1.31, Merck) and arylsulfatase (EC No. 3.1.6.1), from Helix Pomatia L. The urine sample 
was then diluted with 2.5 ml of water and loaded on a HCX solid phase extraction (SPE) 
cartridge, previously conditioned with 1 ml of methanol and 1 ml of water. After passage of 
the sample, the cartridge was washed with 1 ml of water, 1 ml of 0.01 M hydrochloric acid, 
and again with 1.0 ml of water. The retained non-basic compounds were first eluted into a 
1.5 ml reaction vial with 1 ml of methanol (fraction 1). The basic compounds were eluted in a 
second step into a different vial with 1 ml of a freshly prepared mixture of methanol/aqueous 
ammonia 32% (98:2 v/v, fraction 2).The elutes were gently evaporated to dryness under a 
stream of nitrogen at 70°C and derivatized by acetylation according to published 
procedures.[
11
] Briefly, acetylation was conducted with 50 µl of an acetic anhydride-pyridine 
mixture (3:2; v/v) for 5 min under microwave irradiation at about 440 W. After evaporation, 
the residue was dissolved in 50 µl of methanol and injected into the GC-MS system.  
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The same experiments were repeated without use of enzymatic hydrolysis to study which 
metabolites of D2PM were excreted as glucuronides / sulfates. 
 
4.3.2 Sample preparation for phase II metabolism studies 
For elucidating the formation of glucuronides and sulfates, 200 µl of urine were mixed with 
200 µl of acetonitrile for protein precipitation, centrifuged at 14.000g for 5 min and the 
supernatant was transferred into an autosampler vial. A 10-µl aliquot of this solution was 
injected into the LC system. 
 
4.4 GC-MS / LC-HRMS settings 
4.4.1 GC-MS apparatus for metabolism studies  
The extracts were analyzed using a Hewlett Packard (HP, Agilent, Waldbronn, Germany) 
5890 Series II gas chromatograph combined with an HP 5972A MSD mass spectrometer and 
an HP MS ChemStation (DOS series) with HP G1034C software version C03.00. The GC 
conditions were as follows: splitless injection mode; column, HP-1 capillary (12 m x 0.2 mm 
I.D.), cross linked methyl silicone, 330 nm film thickness; injection port temperature, 280°C; 
carrier gas, helium; flow-rate 1 ml/min; column temperature, programmed from 100-310°C at 
15°/min, initial time 3 min, final time 8 min. The MS conditions were as follows: full-scan 
mode, m/z 50-550 u; electron impact (EI) mode, ionization energy, 70 eV; ion source 
temperature, 220°C; capillary direct interface, heated at 260°C. 
 
4.4.2 LC-HR-MS/MS apparatus for identification of phase I and II metabolites 
D2PM and its metabolites were analyzed using a ThermoFisher Scientific (TF, Dreieich, 
Germany) Accela LC system consisting of a degasser, a high pressure quaternary pump and a 
HTC PAL autosampler (CTC Analytics AG, Zwingen, Switzerland), coupled to a TF Q 
Exactive system equipped with heated electrospray ionization II (HESI-II) source. The LC 
conditions were the same as described previously.[
12
]
 
The MS settings were as follows. The 
mass spectrometer was operated in the positive ionization mode. The ionization voltage, 
capillary temperature, vaporizer temperature, sheath gas, and auxiliary gas were set to 3.0 kV, 
380 °C, 350 °C, 60 and 20 au, respectively.  
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Nitrogen was used for spray stabilization, for collision-induced dissociation experiments in 
the higher energy collision dissociation (HCD) cell, and as the damping gas in the curved 
linear ion trap (C-trap). The mass spectrometer acquired full-scan data (m/z 50 – 750) at a 
resolution of 70,000 (full width at half maximum, FWHM at m/z 200) and a data-dependent 
MS/MS scan at a resolution of 35,000 (FWHM at m/z 200). The parent ion was selected in the 
quadrupole (isolation window 1.5 u) and subsequently fragmented in the HCD, operating at a 
collision energy set to 35 eV (m/z 400). A full scan (m/z 50-750) of all fragmented ions 
originating from the parent ion was performed. 
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5 RESULTS AND DISCUSSION 
5.1 Identification of D2PM metabolites  
After the experimental procedure of SPE and acetylation by full-scan EI after GC 
separation,[
11
] the phase I metabolites of D2PM could be identified in rat urine. To 
distinguish between metabolic acetylation and formation of the acetyl derivatives by 
derivatization, one non- derivatized extract was also analyzed.  
 
In accordance to the fragmentation rules described by e.g. McLafferty and Turecek and Smith 
and Busch, the formation of fragments in the parent compound was interpreted and compared 
with the fragments detected in the EI mode of the urinary extracts.[
13,14
]
    
 
From this formation of fragments the structure of the postulated metabolites could be 
deduced.  
Fig. 2 depicts the EI mass spectra of the metabolites and the corresponding gas 
chromatographic retention indices (RI). The assumed structures and the prevailing 
fragmentation pattern can be seen in Fig. 3. 
HR-MS/MS was used to record ESI spectra with the intention to approve the postulated 
metabolites and the fragmentation pattern. Also phase II metabolites could be identified by 
HR-MS/MS. Table 1 shows the metabolites in their characteristic ionized fragments after HR-
MS/MS.   
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Figure 2.  EI mass spectra and gas chromatographic retention indices 
(RI) of D2PM and its metabolites arranged according to their RI. 
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                                                   Figure 2 continued 
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                                                 Figure 2 continued 
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Figure 3. Proposed structures and predominant fragmentation patterns of 
D2PM and its metabolites. The numbers correspond to them in Figure 2. The 
wavy bonds symbolize that a definite assignment to a particular isomer was 
not possible. 
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5.2 Proposed fragmentation patterns for identification of phase I metabolites by 
GC-MS 
 
The importance for the metabolic processes in relation to the characteristic EI-MS fragments 
is discussed here. Figs. 2 and 3 show the EI spectra of the metabolites and their proposed 
structure with the suggested fragmentation pattern, respectively. Suggesting the formation of 
intramolecular hydrogen bonds between the amine at the pyrrolidine ring and the aliphatic 
alcohol group, acetylation of the alcohol moiety was not observable in any of the recorded 
spectra. The same assumption applies for the acetyl group and the aliphatic alcohol group in 
the derivatized molecules. 
Furthermore, the D2PM-HO-pyrrolidinyl-metabolites depicted in spectra and structure nos. 7 
and 8 could also not be detected as acetyl derivatives. It can be supposed that the metabolic 
hydroxylation at the pyrrolidine ring takes place in position 2 of the pyrrolidine ring causing 
the formation of hydrogen bonds between the amine and the hydroxyl group. Therefore 
acetylation at the hydroxyl group or the amine might not be possible. 
The spectrum no. 1 shows the acetylated D2PM. The most prominent signals are at m/z 70, 
also representing the base peak, 77, 105,113, 165, and 181. α-Cleavage leads to the formation 
of the two prominent ions at m/z 70 and m/z 181, representing the pyrrolidine ring and the 
diphenylmethanol part. The ion at m/z 77 stands for the phenyl rings. The diphenyl part of the 
molecule is represented by the ion at m/z 165 (no.1). The ion at m/z 105 represents the 
phenylmethanol part (no.1).  
In spectra nos. 1, 11, and 12 prominent signals at m/z 70 and 113 could be detected. As the 
ion at m/z 70 represents the pyrrolidine ring, it can be suggested that the ion at m/z 113 
represents the acetylated pyrrolidine ring before the loss of the acetyl group (43 u).  
Besides the detection of the metabolites a formation of artifacts by the loss of water during the 
GC could be observed. Spectrum no. 2 shows the parent compound after dehydration during 
GC. The diphenyl part and the phenyl rings are again represented by the ions at m/z 77 and 
165. The loss of the acetyl group is indicated by the ion at m/z 234. Furthermore, 
benzophenone artifacts (nos. 3-5) could be detected as it has been described before by Wood 
et al.[
8
]
 
The metabolites represented by spectra nos. 6-8 show single metabolic hydroxylation at the 
pyrrolidine ring resulting in the detection of the ion at m/z 85 instead of m/z 70. As the mass 
spectra no. 7 and 8 appear to be nearly identical the detection of isomers can be deduced. The 
exact position of the hydroxyl group cannot be determined.  
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Spectrum nos. 9 and 13 indicate the following oxidation of the pyrrolidinyl-hydroxyl group to 
the corresponding ketone. The pyrrolidine ring with the oxo group is represented by the ion 
m/z 84. As the metabolite no. 13 could not be acetylated at the nitrogen it can be suspected 
that the oxo group is located in position 2. Intramolecular hydrogen bonds might be the 
reason for the inability of derivatization. Besides that, the location of ketones in the 
pyrrolidine ring at position 2 has been described before.
 [15]
 
Hydroxylation at the phenyl ring could be observed in the metabolites represented by spectra 
nos. 10-13. The ion at m/z 241 represents the diphenyl-methanol part after acetylation at the 
metabolically hydroxylated phenyl ring. The ion at m/z 199 shows the corresponding part of 
the molecule after loss of the acetyl group. Spectra nos. 11 and 12 show two detected isomers 
with metabolic hydroxylation of the phenyl ring in different positions. Again, the exact 
position of the hydroxyl group cannot be deduced.  
 
5.3 Identification of phase I and II metabolites by LC-HR-MS/MS 
All the phase I metabolites that were identified by GC-MS could be detected and confirmed 
using LC-HR-MS/MS procedures. Furthermore, two phase II metabolites could be identified, 
namely phenylhydroxy-oxo-D2PM glucuronide and phenylhydroxy-D2PM glucuronide. Here 
the glucuronides were detected with a much lower signal abundance than the phase I 
metabolites. In Table 1, all the detected metabolites including the glucuronides are listed with 
the measured accurate masses of the protonated molecule and also the characteristic fragment 
ions. The corresponding calculated exact masses and the proposed elemental composition are 
also depicted. 
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Metabolites and characteristic ions [m/z] Calculated exact masses [u] Elemental compositions 
D2PM, 254.1537 
236.1431 
208.1119 
158.0963 
130.0651 
254.1539 [M+H]+ 
236.1434 
208.1121 
158.0964 
130.0651 
C17H20NO 
C17H18N 
C15H14N 
C11H12N 
C9H8N 
D2PM-M (oxo-), 268.1329 
250.1224 
222.0912 
196.1120 
179.0854 
268.1332 [M+H]+ 
250.1226 
222.0913 
196.1121 
179.0855 
C17H18NO2 
C17H16NO 
C15H12NO 
C14H14N 
C14H11 
D2PM-M (HO-pyrrolidinyl-), 270.1485 
252.1379 
210.1275 
168.0806 
100.0760 
270.1489 [M+H]+ 
252.1383 
210.1277 
168.0808 
100.0757 
C17H20NO2 
C17H18NO 
C15H16N 
C12H10N 
C5H10NO 
D2PM-M (HO-phenyl-), 270.1487 
252.1379 
174.0910 
158.0962 
130.0650 
270.1489 [M+H]+ 
252.1383 
174.0913 
158.0964 
130.0651 
C17H20NO2 
C17H18NO 
C11H12NO 
C11H12N 
C9H8N 
D2PM-M (HO-phenyl-oxo-), 284.1278 
266.1171 
238.0860 
212.1068 
195.0804 
284.1281 [M+H]+ 
266.1176 
238.0863 
212.1070 
195.0804 
C17H18NO3 
C17H16NO2 
C15H12NO2 
C14H14NO 
C14H11O 
D2PM-M (di-HO-), 286.1424 
268.1329 
250.1224 
222.0911 
196.1119 
286.1438 [M+H]+ 
268.1332 
250.1226 
222.0913 
196.1121 
C17H20NO3 
C17H18NO2 
C17H16NO 
C15H12NO 
C14H14N 
D2PM-M (HO-phenyl-)glucuronide, 446.1810 
252.1381 
274.0908 
158.0963 
130.0650 
446.1810 [M+H]+ 
252.1383 
174.0913 
158.0964 
130.0651 
C23H28NO8 
C17H18NO 
C11H12NO 
C11H12N 
C9H8N 
D2PM-M (HO-phenyl-oxo-)glucuronide, 460.1600 
266.1172 
238.0860 
212.1067 
195.0804 
460.1602 [M+H]+ 
266.1176 
238.0863 
212.1070 
195.0804 
C23H26NO9 
C17H16NO2 
C15H12NO2 
C14H14NO 
C14H11O 
 
 
 
 
 
 
Table 1.  List of D2PM and its phase I and II metabolites, the measured 
accurate masses of their protonated molecule and characteristic fragment 
ions, the corresponding calculated exact masses, and the proposed elemental 
compositions 
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5.4 Proposed metabolic pathway 
Fig. 4 shows all the metabolic steps that have been explained above. As initial metabolic steps 
the hydroxylation at the pyrrolidine ring and the phenyl ring could be deduced. The 
hydroxylation at the pyrrolidine ring was followed by the oxidation to the corresponding 
ketone. Combination of the introduction of a phenolic hydroxy group and the hydroxylation at 
the pyrrolidine ring as well as the oxidation to the corresponding ketone could be detected. 
Additionally the parent compound could be detected unchanged. 
  
 
                                              
 
 
 
 
 
 
Figure 4.  Structure of D2PM with arrows indicating the areas of the 
described metabolic reactions. 
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6 CONCLUSIONS 
This study could reveal the extensive metabolism of the synthetic drug D2PM in the rat. 
Several phase I and II metabolites could be identified using GC-MS and LC-HR/MS 
techniques. Due to the huge increase of recreational drug abuse and the resulting health risks 
for the consumers, the importance of appropriate screening procedures has grown. Therefore 
and supposing that the kinetic processes in rats and humans are similar, this study could serve 
as a basis for developing suitable screening strategies for detection of a D2PM intake. This 
will be investigated in a further study. 
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8 ABBREVIATIONS 
 
D2PM    diphenyl-2-pyrrolidinemethanol 
 
GC-MS   gas chromatography- mass spectrometry 
 
LC-MS   liquid chromatography- mass spectrometry 
 
LC-HRMS   liquid chromatography- high resolution- mass spectrometry 
 
MS/MS   tandem mass spectrometry 
 
IUPAC   International Union of Pure and Applied Chemistry 
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